ATAI Investor Day Presentation Deck

Development program overview: lead compounds, lead indications and stage of development Lead Compound PCN-101/R-ketamine RL - 007/Compound² DMX-1002/lbogaine GRX-917/Deuterated etifoxine NN-101/N-acetylcysteine KUR-101/Deuterated Generalized Anxiety Disorder Mild Traumatic Brain Injury Opioid Use Disorder mitragynine EMP-01/MDMA derivative Post-Traumatic Stress Disorder RLS-01/Salvinorin A VLS-01/DMT Lead Indication Treatment-Resistant Depression atai LIFE SCIENCES Cognitive Impairment Associated with Schizophrenia Opioid Use Disorder Preclinical Treatment-Resistant Depression Treatment-Resistant Depression Phase 1 Phase 2 E LIMITED TO EQUITY INTEREST Developing COMP360 therapy, with psychological support from special trained therapists, for treatment - resistant depression. Phase 2b topline data read out in Nov'21. Developing DMX-1001, a formulation of noribogaine, as a potential at-home maintenance therapy for OUD. Preclinical stage Note: DMT = N,N-dimethyltryptamine; MDMA = 3,4-Methylenedioxymethamphetamine. (1) Perception, Recognify, DemeRx IB and Neuronasal are all variable interest entities; GABA is a non-consolidated VIE with operational involvement through MSA model, including Srinivas Rao serving as CMO; EmpathBio, Revixia and Viridia are wholly-owned subsidiaries; COMPASS Pathways and DemeRx NB are non-controlling equity interests. (2) RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt. Phase 3 Affiliate Company¹ Perception Neuroscience Recognify Life Sciences DemeRx IB GABA Therapeutics Neuronasal Kures Empath Bio Revixia Life Sciences Viridia Life Sciences COMPASS Pathways DemeRx NB 15

View entire presentation